Clinical Trial: POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07916311) titled 'POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions' on Oct. 29.

Brief Summary: This prospective, multicenter diagnostic accuracy study will evaluate whether POSLUMA (flotufolastat F 18) PET/MRI or PET/CT can detect clinically significant prostate cancer, defined as Gleason score 7 or higher, in adult men with PI-RADS 3 lesions on recent multiparametric MRI and a clinical indication for prostate biopsy. Participants will undergo a research-only POSLUMA PET scan before targeted and systematic prostate biopsy. PET imaging metrics and clinical variables will be compared with histopathology. Research PET results will not be used to guide ...